4D Molecular Therapeutics, Inc. FDMT 深 沪
等待开盘 07-06 09:30:00 美东时间
13.00
+0.310
+2.44%
华盛通- 最 高13.395
- 今 开12.87
- 成交量 100.28万股
- 最 低 12.63
- 昨 收 12.69
- 总市值 6.80亿
- 52周最高 14.00
- 市盈率 静 --
- 换手率 1.92%
- 52周最低 4.11
- 委 比 59.34%
- 总股本 5227.63万
- 历史最高 55.11
- 量 比 0.60
- 振 幅 6.03%
- 历史最低 2.235
- 每 手 1
- 风险率 1.98%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多摩根士丹利维持对4D Molecular Therapeutics（FDMT）的持有评级
摩根士丹利医疗健康板块分析师犹大·弗罗默维持4D分子治疗公司“持有”评级，该股最新收盘价为12.88美元。弗罗默的股票推荐平均回报率为6.7%，推荐成功率达5...
06-30 20:06
4DMT完成4D-150用于湿性年龄相关性黄斑变性的4FRONT-2全球三期临床试验入组
4D Molecular Therapeutics（纳斯达克代码：FDMT）宣布其针对湿性AMD的全球III期临床试验4FRONT-2已完成全部患者入组，进度较...
06-29 20:09
4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD
4D Molecular Therapeutics announced the completion of global enrollment for the 4FRONT-2 Phase 3 clinical trial for 4D-150 in wet AMD, approximately 4 months ahead of initial projections and with over-enrollment (N>500). Final patient randomization is expected in Q3 2026, and 52-week topline data is anticipated in H2 2027. The high enrollment rate reflects strong interest from patients and investigators, highlighting the potential of 4D-150 to ad...
06-29 12:00
Vivani Medical names August Moretti to board as Dean Baker retires
Vivani Medical names August Moretti to board as Dean Baker retires Vivani Medical named August J. Moretti to its board, replacing retiring director Dean Baker. Moretti becomes audit committee chair, joining the compensation committee. Moretti previously served as CFO of 4D Molecular Therapeutics thr
06-26 19:30
Vivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of Dr. Dean Baker
Vivani Medical, Inc. announced the appointment of August Moretti to its board of directors, effective immediately, and the retirement of Dr. Dean Baker. Moretti, with extensive experience in finance and operations, will serve as chair of the Audit Committee and member of the Compensation Committee. Baker, who served as chair of both the Audit and Compensation Committees, contributed significantly to the company's strategic decisions, including th...
06-26 11:30
4D Molecular Therapeutics Stockholders Back Directors and Governance
4D Molecular Therapeutics ( ($FDMT) ) just unveiled an update. On June 17, 2026...
06-23 05:27
4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics granted 66,900 RSUs to seven new non-executive employees on June 9, 2026, under its 2025 Employment Inducement Award Plan. The Company, focused on advanced therapies for blinding retinal diseases and cystic fibrosis, has its lead product 4D-150 in Phase 3 for wet AMD and DME, and 4D-710 as the first gene therapy for CFTR delivery in cystic fibrosis. All products remain in clinical or preclinical development and are not F...
06-12 20:05
4DMT to Participate in Upcoming Investor Conferences
4DMT announced that its management will participate in investor conferences in June, presenting at the Jefferies Global Healthcare Conference on June 3 and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9. The company is advancing therapeutic candidates targeting blinding retinal diseases and cystic fibrosis, with 4D-150 in Phase 3 for wet AMD and 4D-710 showing potential for CF treatment. Webcasts of the presentations will be...
05-27 12:00
4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics granted 14 new non-executive employees 141,100 RSUs under its 2025 Employment Inducement Award Plan. The company is advancing innovative therapies with potential to transform treatment paradigms, including 4D-150 for retinal diseases and 4D-710 for cystic fibrosis. All product candidates are in clinical or preclinical development.
05-15 20:05
